Anyone seen this? He discovered that people with cancer tumors lacked peptides in their blood and urine whereas people free of cancer have an abundance of these peptides. So he created a treatment that utilizes "antineoplastons." He also studied genes that tell the body to kill tumors.



http://www.imdb.com/title/tt5491934/

Here's another documentary of his:

https://www.youtube.com/watch?v=rBUGVkmmwbk

A commentator in response to a skeptic posted this:

~ documented court evidence: 200,000 pages of notes and patient records seized in a raid by FDA.

~ Followed by Five grand jury trials

~ Followed by Five acquittals.

~ Followed by Former jurors joining protesters ( cured patients) outside these same court hearings.

~ Followed by many many Patients volunteering testimony of support in 2 congressional Inquiries (under oath)

~ Followed by FDA and NCI admitting they do not question the validity of the antineoplastons

~ Followed by documented Phase I & II trial results far superior to the comparative chemo & radiation trial results

~ Followed by

Scientific Publications

Dr. S.R. Burzynski and his associates continuously report new scientific information. The following is a list of publications that excludes articles published before 2010.

Targeted Therapy

Burzynski, S.R., Burzynski, G.S., Brookman, S. A case of sustained objective response of recurrent/progressive diffuse intrinsic pontine glioma with phenylbutyrate and targeted agents. J Cancer Ther 2015;6:40-44.

Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of glioblastoma multiforme. J Cancer Ther 2014;5:1423-1437.

Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in colorectal cancer after failure of second-line therapy – A potential strategy for improved survival. J Cancer Ther 2014;5:1270-1288.

Burzynski, S.R., Burzynski, G.S. Long-term progression-free survival of recurrent glioblastoma multiforme treated with a combination of targeted agents: A case report. AT-14. Neuro Oncol 2014;16(Suppl. 5):v11.Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S.

Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in recurrent advanced pancreatic cancer – A potential strategy for improved survival. J Cancer Ther 2014;5:1072-1091.

Burzynski, S.R., Burzynski, G.S., Janicki, T.J. Recurrent glioblastoma multiforme, a strategy for long-term survival. J Cancer Ther 2014;557-976.

Burzynski, S.R, Nagy-Kubove, E.Treatment of esthesioneuroblastoma and non-small cell lung cancer with phenylbutyrate. Journal of Cancer Therapy 2011;2:518-522.

~ Followed by:

Clinic Trials

Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent anaplastic astrocytoma. Final report (Protocol BT-15). Cancer ClinOncol 2015; in press.

Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas. The report on non-diffuse intrinsic pontine glioma (Protocol BT-11). J Cancer Ther 2015;6:334-344.

Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma. Final report (Protocol BT-08). Cancer ClinOncol 2015;4(1):28-38.

Burzynski, S.R., Janicki, T.J., Marszalek, A., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas final report (Protocol BT-11). AT-15. Neuro Oncol 2014;16(Suppl. 5):v11.

Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme. Final report (Protocol BT-21). J Cancer Ther 2014;546-956.

Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A., Brookman, S. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors. Final report (Protocol BT-22). J Cancer Ther 2014;577-988.

Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with high-grade glioma. Final report (Protocol BT-06), and review of recent trials. J Cancer Ther 2014;5:565-577.

Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Child’s Nervous System 2014;30(12):2051-2061.

Burzynski, S.R., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on protocol BT-22. CT-004. Neuro-Oncology 2014;16(Suppl. 1)10

Burzynski, G., Burzynski, S.R., Janicki, T., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme based on protocol BT-21. NO-020. Neuro-Oncology 2013;15(Suppl. 3)ii103.

Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in pediatric recurrent diffuse intrinsic pontine glioma. NO-021. Neuro-Oncology 2013;15(Suppl. 3)ii103.

Janicki, T., Burzynski, S., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 (ANP) in children with high-grade glioma (Protocol BT-06). NO-058. Neuro-Oncology 2013;15(Suppl. 3)ii112.

~ Followed by:

Case Reports

Janicki, T.J., Burzynski, G.S., Burzynski, S.R. Long-term survival (over 15 years) of pathologically confirmed recurrent glioblastoma multiforme: A case report. AT-28. Neuro Oncol 2014;16(Suppl. 5):v14-15.

Burzynski, G.S., Janicki, T.J., Marszalek, A., Burzynski, S.R. Long-term survival (>20 years) of a child with brainstem glioma treated with antineoplastons A10 and AS2-1: A case report. PT-02. Neuro Oncol 2014;16(Suppl. 5):v175.

Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Long-term survival (> 13 years) in a child with recurrent diffuse pontine gliosarcoma: the case report. Journal of Pediatric Hematology/Oncology 2014;36(7):e433-e439.

Burzynski, G., Janicki, T., Burzynski, S.R., Marszalek, A. Long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report. HG-017. Neuro-Oncology 2014;16(Suppl. 1)44.

Janicki, T., Burzynski, S.R., Burzynski, G., Marszalek, A. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report. MB-039-020. Neuro-Oncology 2014;16(Suppl. 1)80.

Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. Long-term survival (over 13 years) in a child with recurrent diffuse pontine gliosarcoma: A case report. NO-089. Neuro-Oncology 2013;15(Suppl. 3)ii120.

~ Followed by:

Review Articles

Burzynski, S.R. Stanislaw R. Burzynski, MD, PhD: Novel cancer research and the fight to prove its worth. Alternative Therapies in Health and Medicine 2012;18(3):54-61.

~ Followed by:

Basic Science

Burzynski, S.R., Patil, S.S. The effect of antineoplastons A10 and AS2-1 and metabolites of sodium phenylbutyrate on gene expression in glioblastoma multiforme. J Cancer Ther 2014;529-945.

Aliev, G., Burzynski, G., Ashraf, G.M., Jabir, N.R., Cacabelos, R., Benberin, V.V., Burzynski, S.R. Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer. SystBiol Free Rad Antioxid 2014; 2325-2347; DOI: 10.1007/978-3-642-30018-9.

Aliev, G., Palacios, H.H., Cacabelos, P., Cacabelos, R., Burzynski, G., Burzynski, S.R. Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer. Drug Designing 2013;2(1):103.

Patil, S.S., Mrowczynski, E., Grela, K., Burzynski, S.R. Phenylacetylglutaminate in combination with phenylbutyrate effectively inhibits growth of brain tumor cells in vitro. Neuro-Oncology 2012;14(Suppl. 3)ii16.

Patil, S.S., Burzynski, S.R., Mrowczynski, E., Grela, K., Chittur, S.V. Phenylacetylglutaminate and phenylacetate in combination upregulate VDUP1, cause cell cycle blockade and apoptosis in U87 glioblastoma cells. Journal of Cancer Therapy 2012;3:192-200.

I could go on for a few more hours if u wish with the work from the NIH and PUBMED...but ur right, "the evidence is functionally zero..."

-Youtube User: abracadabra